Private Advisor Group LLC trimmed its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 38.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...

led to a 4.3% drop in Biogen's stock price following the announcement. For the current fiscal year, ending in December, analysts expect BIIB’s EPS to plunge 3.9% to $15.83 on a diluted basis.

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Biogen Inc.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Allworth Financial LP lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 53.6% during the fourth quarter, Holdings Channel reports. The firm owned 548 shares of the ...

Blue Trust Inc. grew its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 21.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company focused on developing and commercializing therapies for neurological and neurodegenerative diseases, including multiple sclerosis ...